Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction

European Respiratory Journal

Volumn 23, Issue 4, 2004, Pages 559-564

  Luijk, B ^a   Kempsford, R D ^b   Wright, A M ^b   Zanen, P ^a   Lammers, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adenosine 5 monophosphate; Airway hyperresponsiveness; Asthma; Exhaled nitric oxide; Fluticasone propionate

Indexed keywords

ADENOSINE PHOSPHATE; BIOCHEMICAL MARKER; CORTICOSTEROID; FLUTICASONE PROPIONATE; LACTOSE; NITRIC OXIDE; PLACEBO; SALBUTAMOL;

ADULT; AIRWAY; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADENOSINE MONOPHOSPHATE; ADMINISTRATION, INHALATION; ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOLOGICAL MARKERS; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; NITRIC OXIDE; PLACEBOS; PROTECTIVE AGENTS; TIME FACTORS;

EID: 1842481244     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00043504     Document Type: Article

References (29)

1. Lipworth BJ. Fortnightly review: Modern drug treatment of chronic asthma. BMJ 1999; 318: 380-384.
2. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Resp Dis 1990; 141: S70-S76.
3. Joos GF, O'Connor B, Anderson SD, et al. Indirect airway challenges. Eur Respir J 2003; 21: 1050-1068.
4. Polosa R. Adenosine-receptor subtypes: Their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease. Eur Respir J 2002; 20: 488-496.
5. Van Schoor J, Joos GF, Pauwels RA. Indirect bronchial hyperresponsiveness in asthma: Mechanisms, pharmacology and implications for clinical research. Eur Respir J 2000; 16: 514-533.
6. Van den Berge M, Meijer RJ, Kerstjens HA, et al. PC(20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 2001; 163: 1546-1550.
7. Prosperini G, Rajakulasingam K, Cacciola RR, et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol 2002; 110: 855-861.
8. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110: 603-606.
9. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: A randomized controlled trial. Am J Respir Crit Care Med 2001; 163: 32-36.
10. Kharitonov SA, Barnes PJ. Clinical aspects of exhaled nitric oxide. Eur Respir J 2000; 16: 781-792.
11. NHLBI/WHO Workshop Report 1995. Global strategy for asthma management and prevention. National Institutes of Health. National Heart, Lung, and Blood Institute, Bethesda, MD, updated April, 2002. Publication No. 95-3659. (Scientific information and recommendations for asthma programs. NIH Publication No. 02-3659).
12. Roca J, Burgos F, Sunyer J, et al. References values for forced spirometry. Group of the European Community Respiratory Health Survey. Eur Respir J 1998; 11: 1354-1362.
13. Sterk PJ, Fabbri LM, Quanjer PhH, et al. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993; 6; Suppl 16, 53-83.
14. Oosterhof Y, Koeter GH, De Monchy JGR, Postma DS. Circadian variation in airway responsiveness to metacholine, propranolol, and AMP in atopic asthmatic subjects. Am Rev Resp Dis 1993; 147: 512-517.
15. American Thoracic Society. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. Am J Respir Crit Care Med 1999; 160: 2104-117.
16. O'Connor BJ, Ridge SM, Barnes PJ, Fuller RW. Greater effect of inhaled budenoside on adenosine 5′-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. Am Rev Resp Dis 1992; 146: 560-564.
17. Van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164: 1127-1132.
18. Kidney JC, Boulet L-P, Hargreave FE, Deschesnes F, Swystun VA, O'Byrne PM. Evaluation of single-dose inhaled corticosteroid activity with an allergen challenge model. J Allergy Clin Immunol 1997; 100: 65-70.
19. Lawrence M, Wolfe J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med 1997; 156: 744-751.
20. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 1998; 157: 698-703.
21. Engel T, Dirksen A, Heinig JH, Nielsen NH, Weeke B, Johansson SA. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy 1991; 46: 547-553.
22. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: S434-S439.
23. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: S440-S446.
24. Ketchell RI, Clarke GW, Jensen MW, Vos TP, Allenby MI, O'Connor BJ. Time course evaluation of the rapid effect of as single dose of inhaled fluticasone propionate on airway hyperresponsiveness to AMP in asthma (abstract). Am J Respir Crit Care Med 2003; A770: D55.
25. Mc Fadden ER. Inhaled glucosteroids and acute asthma; therapeutic breakthrough or nonspecific effect? Am J Respir Crit Care Med 1998; 157: 677-678.
26. Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: A novel therapeutic target in asthma? Trends Pharmacol Sci 1998; 19: 148-153.
27. Kumar SD, Brieva JL, Danta I, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med 2000; 161: 918-921.
28. Ketchell RI, Jensen MW, Clark GW, Allenby MI, O'Connor BJ. Rapid effect of single dose inhaled glucocorticosteroid on airway hyperresponsiveness to AMP in asthma is not molecule dependent (abstract). Am J Respir Crit Care Med 2003; A770: D54.
29. Anderson S, Smith CM. Osmotic challenges in the assessment of bronchial hyperresponsiveness. Am Rev Resp Dis 1991; 143: S43-S46.